Egrifta (Tesamorelin) Dosing in Hepatic Impairment

How Tesamorelin Works: Mechanism of Action

Tesamorelin is a synthetic 44-amino-acid analogue of human growth hormone-releasing hormone (GHRH) with a trans-3-hexenoic acid modification at the N-terminus. This structural change protects the molecule from rapid enzymatic cleavage by dipeptidyl peptidase IV (DPP-IV), extending its half-life compared to endogenous GHRH [1]. After subcutaneous injection, tesamorelin binds GHRH receptors on anterior pituitary somatotroph cells, triggering cyclic AMP-mediated signaling that releases stored growth hormone (GH) into circulation.

The GH pulse then acts on hepatocytes and other tissues to stimulate insulin-like growth factor-1 (IGF-1) production. IGF-1 drives lipolysis in visceral adipose depots, which is the therapeutic basis for treating HIV-associated lipodystrophy [3]. The pulsatile, receptor-mediated release pattern distinguishes tesamorelin from exogenous GH administration. Because tesamorelin works through the body's own feedback loop, supraphysiologic GH spikes are less likely than with direct GH injection, though IGF-1 levels still require monitoring [4].

Peak tesamorelin plasma concentrations occur approximately 0.15 hours after injection, with an elimination half-life of 26 minutes in healthy subjects and 38 minutes in HIV-infected patients [5]. The peptide is degraded by circulating and tissue-bound proteases rather than by hepatic cytochrome P450 enzymes. This proteolytic clearance pathway is the central pharmacokinetic fact relevant to hepatic impairment dosing decisions.

Why the FDA Label Does Not Mandate Hepatic Dose Adjustment

The Egrifta SV prescribing information does not include a specific dose modification for patients with mild, moderate, or severe hepatic impairment [5]. No dedicated hepatic impairment pharmacokinetic study has been published for tesamorelin. The absence of a formal recommendation reflects two pharmacological realities.

First, tesamorelin undergoes peptidase-mediated catabolism. Peptide hormones of this size are broken down by ubiquitous endopeptidases and exopeptidases in plasma, kidney, and peripheral tissues [6]. Hepatic phase I and phase II metabolism play a negligible role. Second, the drug does not bind significantly to plasma proteins in a manner that would be disrupted by reduced hepatic synthetic function (such as low albumin in cirrhosis).

The Endocrine Society's 2014 clinical practice guideline on GH use in adults does not single out hepatic impairment as requiring GH-axis dose modification, though it does recommend titrating any GH-based therapy to IGF-1 levels rather than fixed dosing [4]. For tesamorelin specifically, the FDA-approved dose remains 2 mg daily regardless of liver status, but the label instructs clinicians to measure IGF-1 at baseline and periodically thereafter [5]. This IGF-1-guided monitoring approach is the practical safeguard for patients with compromised hepatic function.

Hepatic Considerations in HIV-Associated Lipodystrophy Patients

Liver disease is common in the exact population tesamorelin treats. A 2015 meta-analysis found that nonalcoholic fatty liver disease (NAFLD) prevalence among people living with HIV on antiretroviral therapy ranged from 13% to 55%, depending on the diagnostic method and cohort [7]. Hepatitis C virus (HCV) coinfection affects roughly 25% to 30% of HIV-positive individuals in Western cohorts, and combined HIV/HCV coinfection accelerates fibrosis progression [2].

These overlapping liver conditions matter for three reasons when prescribing tesamorelin.

IGF-1 production depends on functional hepatocytes. The liver produces approximately 75% of circulating IGF-1 [8]. In patients with significant fibrosis or cirrhosis (Child-Pugh B or C), baseline IGF-1 may already be low, and the hepatic response to GH stimulation can be blunted. A patient with advanced liver disease might show a reduced VAT response to tesamorelin because the downstream IGF-1 signal is attenuated. No published trial has stratified tesamorelin efficacy by liver fibrosis stage.

Visceral fat reduction may benefit hepatic steatosis. Tesamorelin's reduction of trunk fat has shown secondary benefits on liver fat. Stanley et al. (2014) reported that tesamorelin decreased hepatic fat fraction by 37% relative to placebo over 12 months in HIV-infected patients with abdominal fat accumulation, measured by magnetic resonance spectroscopy [9]. This finding suggests a potential therapeutic benefit for the very liver pathology common in this population, though tesamorelin is not FDA-approved for NAFLD treatment.

GH stimulation can transiently worsen insulin resistance. GH is a counter-regulatory hormone. The Falutz et al. (2007) trial reported that tesamorelin-treated subjects had a small but statistically significant increase in fasting glucose compared to placebo (mean increase of 0.34 mmol/L) [1]. In patients with hepatic impairment who already have impaired gluconeogenesis regulation or portal hypertension-related insulin resistance, this metabolic effect warrants closer glucose monitoring.

Pharmacokinetic Profile and What Changes with Liver Disease

Tesamorelin's pharmacokinetics in the labeled population (HIV-infected adults) show rapid absorption (Tmax ~9 minutes), a short terminal half-life (26 to 38 minutes), and dose-proportional exposure between 1 mg and 2 mg [5]. Bioavailability is approximately 4% owing to the typical subcutaneous peptide absorption and first-pass proteolytic degradation at the injection site.

In liver disease, the parent drug's clearance is unlikely to change materially because proteases, not hepatocytes, break it down. The downstream effect is the variable: hepatic IGF-1 synthesis. A 2001 study by Donaghy et al. demonstrated that patients with alcoholic cirrhosis (Child-Pugh B/C) had GH resistance, with elevated GH levels but depressed IGF-1, due to reduced hepatic GH receptor expression [10]. While this study examined endogenous GH signaling rather than tesamorelin-stimulated GH, the principle applies. The drug may still release GH effectively from the pituitary, but the liver may not translate that GH pulse into proportionate IGF-1 production.

For practical dosing, this means clinicians should not interpret a low IGF-1 response in a cirrhotic patient as a reason to increase the tesamorelin dose above 2 mg daily. The bottleneck is hepatic receptor responsiveness, not insufficient GH stimulus.

Monitoring Recommendations for Patients with Liver Disease

No society guideline specifically addresses tesamorelin monitoring in hepatic impairment. The following recommendations synthesize the FDA label [5], the Endocrine Society GH guideline [4], and hepatology consensus practice.

IGF-1 levels. Measure at baseline, at 3 months, and every 6 months thereafter. The target range is an age-adjusted IGF-1 within the upper half of normal. If IGF-1 exceeds the upper limit of normal on two consecutive measurements, consider discontinuation [5]. In patients with advanced fibrosis, expect lower baseline IGF-1 and a blunted treatment response.

Liver function tests. Obtain AST, ALT, alkaline phosphatase, and total bilirubin at baseline and every 3 to 6 months. The Egrifta SV label does not list hepatotoxicity as a labeled adverse effect, but given the population's high baseline liver disease burden, tracking hepatic transaminases is standard of care [7].

Fasting glucose and HbA1c. Check at baseline and every 3 months for the first year. GH-mediated insulin resistance can be clinically significant in patients who already have hepatic insulin resistance from cirrhosis or NAFLD [1]. If HbA1c rises above 6.5% or fasting glucose exceeds 126 mg/dL, reassess the risk-benefit ratio of continued therapy.

FIB-4 index or transient elastography. For patients with known NAFLD or HCV coinfection, a fibrosis assessment at baseline helps stratify expectations. Patients with FIB-4 scores above 3.25 (suggestive of advanced fibrosis) may have diminished IGF-1 response and should be monitored more closely for lack of efficacy [11].

Body composition. The FDA label recommends reassessing VAT reduction after 6 months and discontinuing if the patient has not shown a meaningful response, as defined by a decrease in trunk fat on DEXA or waist circumference [5]. In hepatic impairment, consider extending the assessment window to 9 months before concluding treatment failure, given the likelihood of reduced IGF-1 generation.

Drug Interactions Relevant to Hepatic Impairment

Tesamorelin itself has a low drug interaction profile because it avoids CYP450 pathways. The downstream GH and IGF-1 effects create indirect interactions worth noting.

GH-induced changes in cortisol metabolism may reduce cortisol availability by increasing 11-beta-hydroxysteroid dehydrogenase type 1 activity. Patients on stable corticosteroid replacement (common in HIV patients with adrenal insufficiency) may need dose reassessment after starting tesamorelin [4]. GH stimulation can also increase CYP3A4 activity, potentially lowering concentrations of drugs metabolized by this enzyme, including certain protease inhibitors (ritonavir, darunavir) and the HCV direct-acting antiviral glecaprevir [5]. For patients on HCV treatment regimens containing CYP3A4 substrates, viral load monitoring after tesamorelin initiation is prudent.

Simeprevir, an older HCV protease inhibitor, is contraindicated in Child-Pugh B or C hepatic impairment and is itself a CYP3A4 substrate [12]. Combining it with tesamorelin in a hepatically impaired patient would layer two sources of pharmacokinetic uncertainty. Current AASLD/IDSA guidelines favor sofosbuvir-based regimens that have fewer CYP interactions, making this a less common clinical scenario in 2026, but it illustrates why a complete medication reconciliation matters before starting tesamorelin in liver-compromised patients.

When to Avoid Tesamorelin Entirely

The FDA label lists active malignancy as a contraindication, along with pregnancy and hypersensitivity to tesamorelin or mannitol [5]. For hepatic impairment specifically, no absolute contraindication exists. Clinical judgment should weigh against prescribing in the following situations:

Decompensated cirrhosis (Child-Pugh C) with ascites and coagulopathy. These patients have profoundly impaired GH-to-IGF-1 conversion, making efficacy unlikely while GH-mediated fluid retention could worsen ascites [10].

Active hepatocellular carcinoma (HCC). IGF-1 signaling has a complex relationship with hepatocarcinogenesis. While low IGF-1 is paradoxically associated with HCC risk in cirrhosis, exogenous stimulation of the GH/IGF-1 axis in a patient with known HCC is not supported by any safety data [13].

Uncontrolled diabetes with hepatic steatohepatitis. If a patient has a HbA1c above 9% and biopsy-confirmed nonalcoholic steatohepatitis (NASH) with ballooning, the GH-mediated insulin resistance from tesamorelin could accelerate metabolic deterioration. Optimize glycemic control first.

Clinical Trial Evidence in the Hepatic Impairment Context

The key Falutz et al. (2007) Phase 3 trial enrolled 412 HIV-infected patients with excess abdominal fat and randomized them to tesamorelin 2 mg or placebo subcutaneously daily for 26 weeks [1]. Tesamorelin produced a 15.2% reduction in VAT by CT scan, compared with a 5.0% increase in the placebo arm (P<0.001). The trial excluded patients with "significant hepatic disease," though this was not precisely defined by Child-Pugh score or fibrosis stage.

A subsequent 52-week extension study by Falutz et al. (2010) confirmed sustained VAT reduction (approximately 18% from baseline) in patients who continued tesamorelin, while those switched to placebo regained visceral fat within 12 weeks [14]. Liver enzymes were collected as safety data, and no signal of drug-induced hepatotoxicity emerged. ALT elevations above 3x the upper limit of normal occurred at similar rates in treatment and placebo arms.

Stanley et al. (2014) specifically measured hepatic fat fraction and found a 37% relative reduction with tesamorelin compared to placebo over 12 months [9]. The study population included patients with mild hepatic steatosis, though patients with cirrhosis were excluded. This remains the strongest evidence that tesamorelin has a favorable effect on liver fat in HIV-associated metabolic disease.

No randomized controlled trial has enrolled patients with Child-Pugh A, B, or C cirrhosis to assess tesamorelin pharmacokinetics or efficacy stratified by hepatic function. This gap in the evidence base is the reason the FDA label neither mandates nor prohibits use in hepatic impairment. Clinicians are left to apply pharmacological first principles and individualized monitoring.

As the Endocrine Society guideline states: "GH replacement should be individualized, starting at low doses and titrating based on clinical response and IGF-1 levels, particularly in patients with comorbidities that may alter GH sensitivity" [4].